The insulin-like growth factor system and, in particular, insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-1 (IGFBP-1) are dysregulated in type 1 and type 2 diabetes. Serum IGF-I levels are low in both forms of diabetes, and this may be in part genetically determined. It is possible that the reduced serum levels of IGF-I are involved in the development of microvascular and macrovascular complications. Fasting serum IGFBP-1 levels are usually low in early type 2 diabetic patients with insulin resistance and hyperinsulinaemia but may be raised in patients with particularly poor glycaemic control and severe beta-cell failure. Treatment with IGF-I/binding protein complexes has been shown to improve glycaemic control in conjunction with insulin and may in future have a place in the treatment of diabetes, potentially to prevent diabetic complications. Serum IGFBP-1 determination may have utility in the assessment of cardiovascular risk and as an indicator for insulin resistance.
Binoux M.The IGF system in metabolism regulation. Diab Metab1995; 21:330-7.
3.
Monzavi R., Cohen P.IGFs and IGFBPs: role in health and disease. Best Pract Clin Endocrinol Metab2002;16:433-47.
4.
Boisclair YR , Rhoads RP, Ueki I., Wang J., Ooi GTThe acid labile subunit (ALS) of the 150KDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol2001;170: 63-70.
5.
Collett-Solberg PF, Cohen P.The role of insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am1996;25:591-614.
6.
Feldmann B., Jehle PM, Mohan S. et al. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF binding proteins. Growth Horm IGF Res2000;10:53-9.
7.
Heald AH, Cruickshank JK, Riste LK et al. Close relation of fasting insulinlike growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia2001;44:333-9.
8.
Holt RIG , Simpson HL, Sonksen PHThe role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diab Med2003; 20:3-15.
9.
Garay-Sevilla ME, Nava LE, Malacara JM, Wrobel K., Perez U.Advanced glycosylation end products, insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) in patients with type-2 diabetes mellitus. Diab Metab Res Rev2000;16:106-13.
10.
Bang P., Nygren J., Carlsson-Skwirut C., Thorell A., Ljungqvist O.Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. J Clin Endocrinol Metab1998;83:2509-15.
11.
Clauson PG, Brismar K., Hall K., Linnarsson R., Grill V.Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type-2 diabetic patients in Sweden . Scand J Clin Lab Invest1998;58:353-60.
12.
Chantelau E. , Kohner EMWhy some cases of retinopathy worsen when diabetic control improves. BMJ1997;315:1105-06.
13.
Henricsson M., Berntorp K., Fernlund P., Sundkvist G.Progression of retinopathy in insulin-treated type-2 diabetic patients. Diabetes Care2002 ;25:381-5.
14.
Giannini S. , Cresci B., Manuelli C. et al. Insulin-like growth factor binding protein production in bovine retinal endothelial cells . Metabolism1997; 46:1367-79.
15.
Janssen Jamjl , Lamberts SWJ.Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol2000;52:1-9.
16.
Simo R., Lecube A., Segura RM, Garcia-Arumi J., Hernandez C.Free insulin like growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy . Am J Ophthalmol2002;134:376-82.
17.
Simo R., Hernandez C., Segura RM et al. Free insulin-like growth factor-I in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case control study. Clin Sci2003;104:223-30.
18.
Gibson JM, Westwood M., Lauszus FF, Klebe JG, Flyvbjerg A., White A.Phosphorylated insulin-like growth factor binding protein-1 is increased in pregnant diabetic subjects. Diabetes1999 ;48:321-6.
19.
Jones JI, D'Ercole AJ, Camacho-Hubner C., Clemmons DRPhosphorylation of insulin-like growth factor (IGF)-binding protein-1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci USA1991;88:7481-5.
20.
Chiarelli F. , Santilli F., Mohn A.Role of growth factors in the development of diabetic complications. Horm Res2000;53:53-67.
21.
Crosby SR, Tsigos C., Anderton CD, Gordon C., Young RJ, White A.Elevated plasma insulin-like growth factor binding protein-1 levels in type-1 (insulin-dependent) diabetic patients with peripheral neuropathy . Diabetologia1992;35:868-72.
22.
Grandis M., Nobbio L., Abbruzzese M. et al. Insulin treatment enhances expression of IGF-I in sural nerves from diabetic patients. Muscle Nerve2001;24:622-9.
23.
Russell JW, Feldman ELInsulin-like growth factor-I IGF-I prevents apoptosis in sympathetic neurons exposed to high glucose. Horm Metab Res1999 ;31:90-6.
24.
Zhuang HX, Snyder CK, Pu SF, Ishii DNInsulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Experimental Neurology1996;140:198-205.
25.
Brand FN, Kannel WB, Evans J., Larson MG, Wolf PAGlucose intolerance, physical signs of peripheral artery disease and the risk of cardiovascular events: The Framingham study. Am Heart J1998;136:919-27.
26.
Miettinen H. , Lehto S., Salomaa V. et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care1998;21:6-75.
27.
Hayden JM, Reaven PDCardiovascular disease in diabetes mellitus type-2: a potential role for novel cardiovascular risk factors. Curr Op Lipidol2000;11:519-28.
28.
Lee WL, Chen JW, Ting CT, Wang PHChanges of the insulin-like growth factor-I system during acute myocardial infarction: implications on left ventricular remodelling. J Clin Endocrinol Metab1999;84:1575-81.
29.
Izhar U., Hasdai D., Richardson DM, Cohen P., Lerman A.Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. Coron Artery Dis2000;11:69-76.
30.
Montani A., Forster L., Tull S., Angaard EE, Ferns GAA.Insulin-like growth factor-I modulates monocyte adhesion to EAhy 926 endothelial cells. Int J Exp Path1996;77:31-5.
31.
Zenobi PD, Holzmann P., Glatz Y., Riesen WF, Froesch ERImprovement of lipid profile in type-2 (non-insulin dependent) diabetes mellitus by insulin-like growth factor-I. Diabetologia1993;36:465-9.
32.
Vaessen N., Heutink P., Janssen JA et al. A polymorphism in the gene for IGF-I: functional properties and risk for type-2 diabetes and myocardial infarction. Diabetes2001;50:637-42.
33.
Janssen Jamjl , Lamberts SWJ.The role of IGF-I in the development of cardiovascular disease in type-2 diabetes mellitus: is prevention possible?Eur J Endocrinol2002;146:467-77.
34.
Rietveld I. , Janssen JA, Hofman A., Pols HA, van Duijn CM, Lambert SWA polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. Eur J Endocrinol2003;148:171-5.
35.
Frayling TM , Hattersley AT, McCarthy AM et al. A putative functional polymorphism in the IGF-I gene. Association studies with type-2 diabetes, adult height, glucose tolerance and fetal growth in UK populations. Diabetes2002;51:2313-16.
36.
Heald AH, Siddals KW, Fraser W. et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type-2 diabetes. Diabetes2002;51:2629-36.
37.
Zarich SW, Nesto RWDiabetic cardiomyopathy. Am Heart J1989;118: 1000-12.
38.
Osterziel KJ , Rank MB, Strohm O., Dietz R.The somatotrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-I and its alterations during growth hormone therapy to cardiac function. Clin Endocrinol2000;53:61-8.
39.
Norby FL, Wold LE, Duan J., Hintz KK, Ren J.IGF-I attenuates diabetesinduced cardiac dysfunction in ventricular myocytes . Am J Physiol Endocrinol Metab2002 ;238:E658-E666.
40.
Gibson JM, Westwood M., Young RJ et al. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab1996;81:860-3.
41.
Heald AH, Cruickshank JK, Riste LK et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia2001;44:333-9.
42.
Hellenius MB , Brismar KE, Berglund BH et al. Effects on glucose tolerance, insulin secretion, insulin-like growth factor-I and its binding protein, IGFBP-1 in a randomised controlled diet and exercise study in healthy middle aged men . J Int Med1995;238:121-30.
43.
Lemne C., Brismar K.Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome: a study in borderline hypertension. Blood Press1998;7:89-95.
44.
Saitoh H., Kamoda T., Nakahara S. et al. Insulin-like growth factor binding protein-1 as a predictor of glucose stimulated hyperinsulinaemia in pre-pubertal obese children. Eur J Endocrinol1999;140:231-4.
45.
Leinonen ES , Salonen JT, Salonen RM et al. Reduced IGFBP-1 is associated with thickening of the carotid wall in type-2 diabetes. Diabetes Care2002;25:1807-12.
46.
Clark RG, Mortensen DL, Reifsynder D., Mohler M., Etcheverry T., Mukku V.Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3): effects on the glycaemic and growth promoting activities of rhIGF-I in the rat. Growth Regul1993:3:50-2.
47.
Clark RG, Mortensen DL, Carlsson LM, Carlsson B., Carmignac D., Robinson ICThe obese growth hormone (GH)-deficient dwarf rat: boy responses to patterned delivery of GH and insulin-like growth factor-I. Endocrinology1996;137:1904-12.
48.
Carroll PV, Umpleby M., Ward GS et al. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion and improves the lipid profile in adults with IDDM . Diabetes1997;46:1453-8.
49.
9. Cheetham TD, Connors M., Clayton K., Watts A., Dunger DBThe relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor (rhIGF-I). Clin Endo1997;46:415-24.
50.
Thrailkill KMInsulin-like growth factor-I in diabetes mellitus: its physiological metabolic effects and potential clinical utility. Diab Technol Ther2000;2:69-80.
51.
Quattrin T., Thrailkill K., Baker L. et al. Improvement of HbA1c without increased hypoglycaemia in adolescents and young adults with type-1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin/ rhIGF-I in IDDM study group. J Pediatr Endocrinol Metab2001;14:267-77.
52.
Thrailkill KM , Quattrin T., Baker L. et al. Cotherapy with recombinant human insulin-like growth factor-I and insulin improves glycaemic control in type-1 diabetes . Diabetes Care1999;22:585-92.
53.
Clemmons DR, Moses AC, McKay MJ, Sommer A., Rosen DM, Ruckle J.The combination of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type-1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab2000;85:1518-24.
54.
Cusi K., DeFronzo R.Recombinant human insulin-like growth factor-I treatment improves metabolic control in type-2 diabetes by ameliorating hepatic and muscle insulin resistance . J Clin Endocrinol Metab2000;85: 3077-84.
55.
Moses AC, Young SCJ, Morrow LA, O'Brien M., Clemmons DRRecombinant human IGF-I increases insulin sensitivity and improves glycaemic control in insulin requiring type-2 diabetes. Diabetes1996;45: 91-100.
56.
O'Connell T. , Clemmons DRIGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab2002;87:4356-60.
